3/8/2021 7:02:41 AM
Health Canada Approves KEYTRUDA As First-line Treatment For MSI-H Or Mismatch Repair Deficient Colorectal Cancer
3/3/2021 6:55:53 AM
Merck Plans To Present New Data From Various HIV Research And Development Programs At CROI 2021
3/1/2021 6:49:32 AM
Merck Announce That FDA Has Accepted For Review NDA For Gefapixant
2/25/2021 4:40:02 PM
Merck Animal Health Completes Acquisition Of Poultry Sense
2/25/2021 6:49:42 AM
Merck To Acquire Pandion Therapeutics For $60 Per Share In Cash
2/4/2021 6:46:30 AM
Merck Q4 GAAP Loss/Shr $0.83; Non-GAAP EPS $1.32
2/4/2021 6:45:03 AM
Merck CEO Kenneth Frazier To Retire; Robert Davis Named Successor
2/1/2021 7:29:55 AM
Merck Receives Positive EU CHMP Opinion For Expanded Approval Of KEYTRUDA
2/1/2021 7:29:05 AM
Merck Names Stephen Mayo To Board, Effective March 15, 2021